|
Multiple Myeloma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Myeloma risk has been associated with low blood levels of monocyte chemotactic protein-3 (MCP-3), macrophage inflammatory protein-1 alpha (MIP-1α), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), fractalkine, and transforming growth factor-alpha (TGF-α).
|
30948485 |
2019 |
|
Multiple Myeloma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was designed to determine the effects of rHuEpo on cancer-associated fibroblasts (CAFs) from monoclonal gammopathy of undetermined significance (MGUS) and MM patients by means of in vitro and in vivo assays. rHuEpo treatment reduces the expression of mRNA levels of fibroblast activation markers, namely alpha smooth actin (αSMA) and fibroblast activation protein (FAP) in MGUS and MM CAFs, and of pro-inflammatory and pro-angiogenic cytokines, including interleukin (IL)-6 and IL-8, vascular endothelial growth factor-A (VEGF-A), fibroblast growth factor-2 (FGF-2), and hepatocyte growth factor (HGF) in MM CAFs.
|
29589107 |
2018 |
|
Multiple Myeloma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Our results imply that the course of disease in MM patients is associated with a polymorphism within the bFGF gene.
|
28373444 |
2017 |
|
Multiple Myeloma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In the present study, mRNA expression and circulating levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), hypoxia inducible factor (HiF)-1α, circulating endothelial progenitor cells (cEPCs) and bone marrow microvessel density (MVD) were evaluated in multiple myeloma (MM).
|
23113684 |
2013 |
|
Multiple Myeloma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, fibroblast growth factor 2 (FGF-2) is found at high levels in patients with multiple myeloma.
|
20192985 |
2010 |
|
Multiple Myeloma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In multiple myeloma (MM), both vascular endothelial (VEGF) and basic fibroblast growth factor (bFGF) promote tumor growth and survival.
|
16278310 |
2006 |
|
Multiple Myeloma
|
0.090 |
Biomarker
|
disease |
LHGDN |
The results showed that FGF-2, VEGF, IL-6r, and TNF-alpha were significantly elevated in MM patients in comparison to controls ( p<0.008) and were significantly higher in stage III disease in comparison to stages I and II ( p<0.03).
|
12574959 |
2003 |
|
Multiple Myeloma
|
0.090 |
Biomarker
|
disease |
LHGDN |
Conversely, stimulation with IL-6 enhanced bFGF expression and secretion by myeloma cell lines (2-fold; P =.02) as well as MM patient cells (up to 3.6-fold; median, 1.5-fold; P =.002).
|
12517814 |
2003 |
|
Multiple Myeloma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Accordingly, neutralizing anti-FGF-2 antibody caused a significant inhibition (ranging from 54% to 68%) of the biological activity exerted on cultured endothelial cells and in the CAM assay by plasma cell CM samples from active MM patients.
|
10216103 |
1999 |